The DOI matches its Crossref record.
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open accessAbstract
Ann Oncol 2019; 00: 128 (doi:10.1093/annonc/mdz173) Supplementary material was erroneously uploaded for this paper but the file was not intended for publication. This has now been removed. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of OncologyVol. 30Issue 8PreviewIn 2018, the predicted number of new breast cancers in 28 European Union (EU) countries was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 000 and mortality of 32.9/100 000, with 98 755 predicted deaths [1]. Worldwide, there was about 2.1 million newly diagnosed female breast cancer cases in 2018, accounting for almost one in four cancer cases among women, and ∼630 000 died of it [2]. Breast cancer incidence has increased since the introduction of mammography screening and continues to grow with the ageing of the population. Full-Text PDF Open Archive
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112651 · Cited by 1,274
Self-citationMittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31953-x · Cited by 1,083
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
Cortesi, L., Rugo, H. S., & Jackisch, C. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00796-4 · Cited by 393
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
Marchiò, C., Annaratone, L., Marques, A., Casorzo, L., Berrino, E., & Sapino, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.016 · Cited by 377
Towards personalized treatment for early stage HER2-positive breast cancer
Goutsouliak, K., Veeraraghavan, J., Sethunath, V., De Angelis, C., Osborne, C. K., Rimawi, M. F., & Schiff, R. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0299-9 · Cited by 287
Metadata
- Authors
- Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 30
- Issue
- 10
- Pages
- 1674
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4243051815
- Cited by
- 512
- References
- 0
- FWCI
- 18.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. https://app.cochat.ai/papers/10.1093/annonc/mdz189
- The paper
- Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. https://doi.org/10.1093/annonc/mdz189
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.